Previous Article | Next Article ![]()
Journal of Virology, December 1998, p. 9683-9697, Vol. 72, No. 12
Departments of Molecular Genetics and
Biochemistry1 and
Cell Biology and
Physiology,2 University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania 15261
Received 4 May 1998/Accepted 25 August 1998
The utility of recombinant herpes simplex virus type 1 (HSV-1)
vectors may be expanded by manipulation of the virus envelope to
achieve cell-specific gene delivery. To this end, an HSV-1 mutant virus
deleted for glycoprotein C (gC) and the heparan sulfate binding domain
of gB (KgBpK
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Recombinant Herpes Simplex Virus Type 1 Engineered
for Targeted Binding to Erythropoietin Receptor-Bearing Cells

gC
) was engineered to encode
different chimeric proteins composed of N-terminally truncated forms of
gC and the full-length erythropoietin hormone (EPO). Biochemical
analyses demonstrated that one gC-EPO chimeric molecule
(gCEPO2) was posttranslationally processed, incorporated
into recombinant HSV-1 virus (KgBpK
gCEPO2),
and neutralized with antibodies directed against gC or EPO in a
complement-dependent manner. Moreover,
KgBpK
gCEPO2 recombinant virus was
specifically retained on a soluble EPO receptor column, was neutralized
by soluble EPO receptor, and stimulated proliferation of FD-EPO cells,
an EPO growth-dependent cell line. FD-EPO cells were nevertheless
refractory to productive infection by both wild-type HSV-1 and
recombinant KgBpK
gCEPO2 virus. Transmission
electron microscopy of FD-EPO cells infected with
KgBpK
gCEPO2 showed virus endocytosis leading
to aborted infection. Despite the lack of productive infection, these
data provide the first evidence of targeted HSV-1 binding to a
non-HSV-1 cell surface receptor.
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of
Medicine, E1240 Biomedical Science Tower, Pittsburgh, PA 15261. Phone:
(412) 648-8106. Fax: (412) 624-8997. E-mail:
joe{at}hoffman.mgen.pitt.edu.
Present address: Onyx Pharmaceuticals, Richmond, Calif.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»